---
stable_id: R-HSA-74730
display_name: Insulin degradation
species: Homo sapiens
summary: 'IDE dimer in the endosome lumen catalyzes the processive degradation of
  insulin into multiple inactive fragments (Manolopoulou et al. 2009; Zhang et al.
  2018)


  Insulin released into the endosome is rapidly degraded.<p>Two enzymes known to be
  present in liver parenchymal cells, insulin-degrading enzyme (IDE) and cathepsin
  D (CTSD) degrade insulin efficiently in vitro, and both are annotated as candidate
  catalysts of this reaction. The identity of the enzyme or enzymes mediating this
  degradation in vivo remains controversial, however. By a variety of immunological
  and enzymological criteria, catalytically active material from rat liver fractions
  exhibited properties distinct from those expected for insulin-degrading enzyme (IDE)
  (Authier et al. 1994), indistinguishable from those expected for cathepsin D (CTSD),
  and sufficient to account for the insulin-degrading activity in these fractions
  (Authier et al. 2002). Nevertheless, IDE deficiency in vivo is associated with abnormal
  insulin turnover, IDE is present at low levels in endosomes and biochemical studies
  indicate that IDE efficiently degrades insulin (Shen et al. 2006; Manopoulou et
  al. 2009; Zhang et al. 2018).<p>The active form of IDE is a dimer with one Zn++
  bound to each protein subunit (Li et al. 2006).'
---

# Insulin degradation
**Reactome ID:** [R-HSA-74730](https://reactome.org/content/detail/R-HSA-74730)
**Species:** Homo sapiens

## Summary

IDE dimer in the endosome lumen catalyzes the processive degradation of insulin into multiple inactive fragments (Manolopoulou et al. 2009; Zhang et al. 2018)

Insulin released into the endosome is rapidly degraded.<p>Two enzymes known to be present in liver parenchymal cells, insulin-degrading enzyme (IDE) and cathepsin D (CTSD) degrade insulin efficiently in vitro, and both are annotated as candidate catalysts of this reaction. The identity of the enzyme or enzymes mediating this degradation in vivo remains controversial, however. By a variety of immunological and enzymological criteria, catalytically active material from rat liver fractions exhibited properties distinct from those expected for insulin-degrading enzyme (IDE) (Authier et al. 1994), indistinguishable from those expected for cathepsin D (CTSD), and sufficient to account for the insulin-degrading activity in these fractions (Authier et al. 2002). Nevertheless, IDE deficiency in vivo is associated with abnormal insulin turnover, IDE is present at low levels in endosomes and biochemical studies indicate that IDE efficiently degrades insulin (Shen et al. 2006; Manopoulou et al. 2009; Zhang et al. 2018).<p>The active form of IDE is a dimer with one Zn++ bound to each protein subunit (Li et al. 2006).
